What are the grades assigned to the recommendations for antenatal corticosteroid use in the late‑preterm period?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

GRADE Recommendations for Antenatal Corticosteroids in the Late-Preterm Period

The Society for Maternal-Fetal Medicine (SMFM) assigns five distinct GRADE recommendations for late-preterm corticosteroid use, ranging from strong recommendations (GRADE 1A) for high-risk singleton pregnancies to conditional recommendations (GRADE 2C) for select populations not studied in the original trial. 1

Breakdown of GRADE Assignments

GRADE 1A - Strongest Recommendation

  • Offer a single course of antenatal corticosteroids (2 doses of 12 mg intramuscular betamethasone 24 hours apart) to patients meeting ALPS trial criteria:
    • Singleton pregnancy between 34 0/7 and 36 6/7 weeks
    • High risk of preterm birth within next 7 days and before 37 weeks
    • This represents high-quality evidence with strong recommendation 1

GRADE 2C - Conditional Recommendation

  • Consider use in select populations not included in the original ALPS trial:
    • Multiple gestations reduced to singleton on or after 14 0/7 weeks
    • Patients with fetal anomalies
    • Those expected to deliver in <12 hours
    • This reflects low-quality evidence with weak recommendation 1

GRADE 1B - Strong Recommendation Against

  • Do not use antenatal corticosteroids in pregnant patients with low likelihood of delivery before 37 weeks
  • Moderate-quality evidence supporting strong recommendation against use 1

GRADE 1C - Strong Recommendation Against (Specific Population)

  • Do not use late preterm corticosteroids in pregnant patients with pregestational diabetes mellitus
  • Risk of worsening neonatal hypoglycemia outweighs benefits
  • Low-quality evidence but strong recommendation due to safety concerns 1

GRADE 1C - Strong Recommendation for Counseling

  • Thoroughly counsel patients at risk for late preterm delivery regarding:
    • Potential risks and benefits of corticosteroid administration
    • Long-term risks remain uncertain
    • Low-quality evidence but strong recommendation for informed consent 1

Understanding the GRADE System in This Context

The GRADE system used here reflects:

  • Number (1 or 2): Strength of recommendation (1 = strong, 2 = conditional)
  • Letter (A, B, or C): Quality of evidence (A = high, B = moderate, C = low)

The strongest evidence (GRADE 1A) applies specifically to the ALPS trial population, which demonstrated clear reduction in respiratory morbidity with betamethasone versus placebo (11.6% vs 14.4%; RR 0.80) and severe respiratory morbidity (8.1% vs 12.1%; RR 0.67) 1.

Key Clinical Caveat

The GRADE 1C recommendation against use in pregestational diabetes is particularly important—despite being based on lower-quality evidence, the strong recommendation reflects the known increased risk of neonatal hypoglycemia in this population, which has been independently associated with developmental delays in preschool-aged children 1. Women with pregestational diabetes were explicitly excluded from the ALPS trial, yet many practitioners began administering late preterm steroids to this population after trial publication 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.